Treatment of drug-induced agranulocytosis with recombinant GM-CSF.
A 53-year male patient, treated for rheumatoid arthritis with sulphasalazine, developed a total agranulocytosis. When this state had prevailed for at least 10 d no bone marrow granulocyte progenitor cells were detectable. Intravenous GM-CSF treatment was initiated 5 d later, and the patient recovered within the next 6 d. GM-CSF treatment for severe agranulocytosis deserves further investigation.
Palmblad
J
J
Division of Hematology, Södersjukhuset, Stockholm, Sweden.
Jonson
B
B
Kanerud
L
L
D000380:Agranulocytosis / Q000139:chemically induced* / Q000628:therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D011994:Recombinant Proteins; D012460:Sulfasalazine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor